First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma

First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma
MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who failed prior chemotherapy. Taking place at the National Cancer Institute at the National Institutes of Health and Washington University in St. Louis, the open-label study (NCT03608618is expected to include 15 participants. It is still recruiting patients.  "The initiation of patient dosing in our first clinical trial with our lead CAR therapeutic candidate is a significant milestone for MaxCyte, validating our streamlined manufacturing process for clinical use," Doug Doerfler, MaxCyte's CEO, said in a press release. "We are extremely pleased to have very experienced investigators at two leading clinical centers conducting this study in solid tumors." CAR T-cell immunotherapy — an approach that consists of collecting a patient’s own T-cells and modifying them in the lab to recognize cancer cells w
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *